Genentech, Inc.

Sanjeev Kothari

Francis Gosselin

Scott J Savage

Jeffrey Stults

Paroma Chakravarty

Hamid Rezaei

Priscilla Mantik

Alexander Mauerer

Piscilla Mantik

The present disclosure relates generally to rapid-release pharmaceutical dosage unit tablets containing a drug that is an inhibitor of the mitogen-activated protein kinase enzyme, a filler and a disintegrant, and to processes for forming the tablets. More specifically, the present disclosure relates to pharmaceutical dosage unit tablets containing cobimetinib, a least one filler, at least one lubricant and at least one disintegrant, and to methods for preparing the tablets from granules formed by dry granulation.

Immediate-release tablets containing combimetinib and methods of making and using the same

Disclosed is (S)-2-(4-chlorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-(isopropylamino)propan-1-one monohydrochloride, forms, formulations, pharmaceutical compositions, processes of manufacturing and methods of use thereof.

Crystalline and mesomorphous forms of an AKT inhibiting pyrimidinyl-cyclopentane compound, compositions and methods thereof

Amorphous form of an AKT inhibiting pyrimidinyl-cyclopentane compound, compositions and methods thereof

Growing community of inventors

South San Francisco, CA, United States of America

Sanjeev Kothari